The global dendritic cell cancer vaccine market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include an increase in the prevalence of cancer, improvement of technology such as drug innovations regarding cancer, an upsurge in awareness about cancer and their available therapies in the market. Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. The main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of the pathogen to T-cells for their identification and elimination from the body. They are rare kinds of leukocytes. Isolated dendritic cells (DCs) loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.
Some other factors that are expected to fuel the market growth include the rise in investments in R&D activities, together with positive results in clinical trials, which are anticipated to drive the growth of the market. Other factors that are boosting the growth of the market include the ability of dendritic cells to target multiple cancer antigen capability, a rise in the geriatric population, and technological advancements. Currently, the three marketed cancer vaccines commercially available in different geographies include Provenge (U.S.), CreaVax-RCC (South Korea), and Tumor Antigen Presenting Cells, such as TAPCells (Chile). Provenge is the first marketed dendritic cell vaccine available in the market. They are targeted to treat prostate cancer, metastatic renal cell carcinoma, melanoma, and prostate cancer.
To Request a Sample of our Report on Dendritic Cell Cancer Vaccine Market: https://www.omrglobal.com/request-sample/dendritic-cell-cancer-vaccine-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Product Type
- By End-Users
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Argos Therapeutics, and Dendreon Corp., among others
Dendritic Cell Cancer Vaccine Market Report by Segment
By Product Type
- CreaVax
- Sipuleucel-T (Provenge)
- Others
By End-Users
- Adults
- Pediatrics
A full Report of Dendritic Cell Cancer Vaccine Market is Available @ https://www.omrglobal.com/industry-reports/dendritic-cell-cancer-vaccine-market
Dendritic Cell Cancer Vaccine Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
